サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1546208

子宮がん治療薬と診断薬の世界市場

Uterine Cancer Therapeutics and Diagnostics

出版日
ページ情報
英文 173 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
子宮がん治療薬と診断薬の世界市場
出版日: 2024年09月03日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 173 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

子宮がん治療薬と診断薬の世界市場は2030年までに282億米ドルに達する見込み

2023年に214億米ドルと推定された子宮がん治療薬と診断薬の世界市場は、2030年には282億米ドルに達し、分析期間2023-2030年のCAGRは4.0%で成長すると予測されます。本レポートで分析したセグメントの1つである子宮内膜がん治療薬および診断薬は、CAGR 4.9％を記録し、分析期間終了までに190億米ドルに達すると予測されます。子宮肉腫治療薬・診断薬セグメントの成長率は、分析期間中CAGR 2.4％と推定されます。

米国市場は推定57億米ドル、中国はCAGR7.5％で成長予測

米国の子宮がん治療薬と診断薬市場は2023年に57億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに64億米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは7.5%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.3%と4.6%と予測されています。欧州では、ドイツがCAGR 1.7%で成長すると予測されています。

世界の子宮がん治療薬と診断薬市場- 主要動向と促進要因まとめ

なぜ子宮体がんの発見と治療が重要なのか？

子宮体がんは、女性が罹患する最も一般的ながんの1つで、主に子宮内膜がんと子宮肉腫が含まれます。早期発見と効果的な治療は、生存率と生活の質を向上させるために非常に重要です。子宮体がんの罹患率が世界的に上昇するにつれ、先進的な治療薬や診断薬に対する需要が高まっています。経膣超音波検査、子宮内膜生検、高度な画像診断法などの技術による早期発見は、治療成績を大幅に改善することができます。さらに、手術、放射線療法、化学療法、ホルモン療法などの個別化された治療アプローチは、特定のがん種や病期をターゲットに進化しており、患者の転帰を改善し、副作用を最小限に抑えます。分子診断学とバイオマーカー検査の統合は、治療を調整する能力をさらに向上させ、患者が腫瘍の遺伝子構成に基づいて最も効果的な治療を受けられるようにしています。

技術の進歩は子宮体がん治療にどのような革命をもたらしているか？

技術革新は、子宮体がんの診断と治療の両方を進歩させる上で極めて重要です。ロボット支援手術のような低侵襲手術手技の登場は、回復時間の短縮と手術成績の改善をもたらし、合併症の少ない低侵襲な選択肢を患者に提供しています。さらに、標的治療薬や免疫療法が開発されたことで、特に進行・再発子宮体がん患者に対する治療に新たな道が開かれました。これらの治療法は、がんの増殖に関与する特定の分子を標的とすることで、従来の化学療法に比べて副作用が少なく、より精密で効果的な治療を可能にします。診断の面では、次世代シーケンサー（NGS）とリキッドバイオプシーが、遺伝子変異を同定し、治療反応をリアルタイムでモニターする強力なツールとして台頭してきています。これらの進歩により、臨床医はより多くの情報に基づいた決断を下し、必要に応じて治療を調整し、より個別化された治療を提供できるようになります。

子宮体がんにおける先進的な診断と治療法の採用を促進するものは何か？

子宮体がんの有病率の増加、特に高齢化した集団や生活習慣に関連した危険因子を持つ集団における子宮体がんの有病率の増加が、先進的な診断法と治療法の採用を促進しています。子宮体がんの症状や早期発見の重要性に対する認識が高まるにつれ、より多くの女性が定期的な検診を受けるようになり、早期診断と治療成績の向上につながっています。さらに、ヘルスケアプロバイダーは個別化医療のアプローチを採用するようになっており、遺伝子検査や分子生物学的検査を活用して治療方針の決定に役立てています。このような精密医療へのシフトは、子宮体がんにおける特定の遺伝子変異と治療効果との関連性を示す調査結果の増加によって裏付けられています。さらに、先進国市場や新興国市場におけるヘルスケア支出の増加は、高度な診断や治療へのアクセスを可能にし、生存率や患者の転帰の改善に寄与しています。腫瘍医、放射線科医、病理医、遺伝カウンセラーを含む集学的ケアチームの役割拡大も、子宮体がん患者に対する包括的で協調的なケアの提供を強化しています。

子宮がん治療薬と診断薬市場の成長を促進する要因は？

子宮がん治療薬と診断薬市場の成長は、診断技術の進歩、個別化治療の選択肢の増加、世界の子宮体がんの有病率の上昇など、いくつかの要因によってもたらされます。分子診断やバイオマーカー主導型治療の開発が進んでおり、これらの技術革新により、よりターゲットを絞った効果的な治療戦略が可能になるため、市場拡大に大きく寄与しています。さらに、定期的な検診や高度な画像診断技術の使用による早期発見が重視されるようになり、診断サービスへの需要が高まっています。子宮体がんに対する意識の高まりとタイムリーな介入の重要性も、最先端治療と診断に対する患者の需要を後押ししています。さらに、先進国市場と新興国市場の両方でヘルスケア支出が増加しているため、こうした先端技術への幅広いアクセスが可能になり、市場の成長をさらに後押ししています。最後に、標的治療薬や免疫療法を含む新規治療薬のパイプラインが拡大しており、これらの治療は進行型や抵抗性の子宮体がん患者に新たな希望をもたらすため、今後も市場の牽引役となることが期待されます。

調査対象企業の例（注目の46社）

  • Becton, Dickinson and Company
  • F. Hoffmann-La Roche AG
  • Merck & Co., Inc.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP15408

Global Uterine Cancer Therapeutics and Diagnostics Market to Reach US$28.2 Billion by 2030

The global market for Uterine Cancer Therapeutics and Diagnostics estimated at US$21.4 Billion in the year 2023, is expected to reach US$28.2 Billion by 2030, growing at a CAGR of 4.0% over the analysis period 2023-2030. Endometrial Carcinomas Therapeutics and Diagnostics, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$19.0 Billion by the end of the analysis period. Growth in the Uterine Sarcomas Therapeutics and Diagnostics segment is estimated at 2.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$5.7 Billion While China is Forecast to Grow at 7.5% CAGR

The Uterine Cancer Therapeutics and Diagnostics market in the U.S. is estimated at US$5.7 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$6.4 Billion by the year 2030 trailing a CAGR of 7.5% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.3% and 4.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.7% CAGR.

Global Uterine Cancer Therapeutics and Diagnostics Market - Key Trends & Drivers Summarized

Why Is Uterine Cancer Detection and Treatment So Vital?

Uterine cancer, one of the most common cancers affecting women, primarily includes endometrial cancer and uterine sarcomas. Early detection and effective treatment are critical for improving survival rates and quality of life. As the incidence of uterine cancer rises globally, the demand for advanced therapeutics and diagnostics has intensified. Early-stage detection through techniques like transvaginal ultrasound, endometrial biopsy, and advanced imaging methods can significantly improve treatment outcomes. Moreover, personalized treatment approaches, including surgery, radiation therapy, chemotherapy, and hormone therapy, have evolved to target specific cancer types and stages, improving patient outcomes and minimizing side effects. The integration of molecular diagnostics and biomarker testing has further refined the ability to tailor treatments, ensuring that patients receive the most effective therapies based on the genetic makeup of their tumors.

How Are Technological Advancements Revolutionizing Uterine Cancer Care?

Technological innovations have been pivotal in advancing both the diagnosis and treatment of uterine cancer. The advent of minimally invasive surgical techniques, such as robotic-assisted surgery, has reduced recovery times and improved surgical outcomes, offering patients less invasive options with fewer complications. Additionally, the development of targeted therapies and immunotherapies has opened new avenues for treatment, particularly for patients with advanced or recurrent uterine cancer. These therapies work by targeting specific molecules involved in cancer growth, allowing for more precise and effective treatment with fewer side effects compared to traditional chemotherapy. On the diagnostics front, next-generation sequencing (NGS) and liquid biopsies are emerging as powerful tools for identifying genetic mutations and monitoring treatment responses in real-time. These advancements enable clinicians to make more informed decisions, adjust treatments as needed, and provide more personalized care.

What Is Driving the Adoption of Advanced Diagnostics and Therapeutics in Uterine Cancer?

The increasing prevalence of uterine cancer, particularly in aging populations and those with lifestyle-related risk factors, is driving the adoption of advanced diagnostics and therapeutics. As awareness of uterine cancer symptoms and the importance of early detection grows, more women are undergoing regular screenings, leading to earlier diagnosis and better treatment outcomes. Additionally, healthcare providers are increasingly adopting personalized medicine approaches, utilizing genetic and molecular testing to guide treatment decisions. This shift towards precision medicine is supported by the growing body of research linking specific genetic mutations to treatment responses in uterine cancer. Furthermore, the rising healthcare expenditures in developed and emerging markets are enabling greater access to advanced diagnostics and treatments, contributing to improved survival rates and patient outcomes. The expanding role of multidisciplinary care teams, including oncologists, radiologists, pathologists, and genetic counselors, is also enhancing the delivery of comprehensive and coordinated care for uterine cancer patients.

What Factors Are Driving the Growth in the Uterine Cancer Therapeutics and Diagnostics Market?

The growth in the Uterine Cancer Therapeutics and Diagnostics market is driven by several factors, including advancements in diagnostic technologies, the increasing availability of personalized treatment options, and the rising prevalence of uterine cancer worldwide. The ongoing development of molecular diagnostics and biomarker-driven therapies is significantly contributing to market expansion, as these innovations allow for more targeted and effective treatment strategies. Additionally, the growing emphasis on early detection through regular screenings and the use of advanced imaging techniques is increasing the demand for diagnostic services. The rising awareness of uterine cancer and the importance of timely intervention are also driving patient demand for cutting-edge therapies and diagnostics. Furthermore, the increasing healthcare expenditure in both developed and emerging markets is enabling broader access to these advanced technologies, further fueling market growth. Finally, the expanding pipeline of new therapeutics, including targeted therapies and immunotherapies, is expected to continue driving the market as these treatments offer new hope for patients with advanced or resistant forms of uterine cancer.

Select Competitors (Total 46 Featured) -

  • Becton, Dickinson and Company
  • F. Hoffmann-La Roche AG
  • Merck & Co., Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Uterine Cancer Therapeutics and Diagnostics - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Incidence of Uterine Cancer Driving Demand forg Advanced Therapeutics
    • Rising Adoption of Personalized Medicine in Cancer Treatment
    • Advancements in Genomic Testing Enhancing Early Diagnosis Capabilities
    • Growing Demand for Minimally Invasive Surgical Techniques
    • Development of Targeted Therapies Creating New Market Opportunities
    • Impact of Aging Population on Uterine Cancer Incidence
    • Increasing Investments in Cancer Research and Development
    • Adoption of AI and Machine Learning in Diagnostic Technologies
    • Rising Awareness and Screening Programs Boosting Early Detection Rates
    • Growing Demand for Combination Therapies in Cancer Treatment
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Uterine Cancer Therapeutics and Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 3: World 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Uterine Sarcomas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Uterine Sarcomas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 6: World 16-Year Perspective for Uterine Sarcomas by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Endometrial Carcinomas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Endometrial Carcinomas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 9: World 16-Year Perspective for Endometrial Carcinomas by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 10: World Uterine Cancer Therapeutics and Diagnostics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Uterine Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 17: USA Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 18: USA Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: USA 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 20: USA Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 23: Canada Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 24: Canada Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: Canada 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • JAPAN
    • Uterine Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 29: Japan Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Japan Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: Japan 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: Japan 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • CHINA
    • Uterine Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 35: China Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: China Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: China 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 38: China Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: China 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • EUROPE
    • Uterine Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 41: Europe Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 42: Europe Historic Review for Uterine Cancer Therapeutics and Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Europe 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Europe 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • FRANCE
    • Uterine Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 50: France Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: France Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: France 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 53: France Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: France 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • GERMANY
    • Uterine Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 56: Germany Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Germany Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Germany 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Germany 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 62: Italy Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Italy Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Italy 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Italy 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Uterine Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 68: UK Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: UK Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: UK 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 71: UK Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: UK 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 74: Spain Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Spain Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Spain 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 77: Spain Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Spain 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 80: Russia Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Russia Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Russia 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 83: Russia Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Russia 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Rest of Europe Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Rest of Europe 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Rest of Europe 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Uterine Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 93: Asia-Pacific Historic Review for Uterine Cancer Therapeutics and Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Asia-Pacific 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Asia-Pacific 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Uterine Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 101: Australia Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Australia Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Australia 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 104: Australia Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Australia 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • INDIA
    • Uterine Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 107: India Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: India Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: India 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 110: India Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: India Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: India 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 113: South Korea Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: South Korea Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: South Korea 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: South Korea 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 119: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: Rest of Asia-Pacific Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: Rest of Asia-Pacific 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Uterine Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 125: Latin America Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 126: Latin America Historic Review for Uterine Cancer Therapeutics and Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: Latin America 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: Latin America 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 134: Argentina Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Argentina Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Argentina 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Argentina 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 140: Brazil Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Brazil Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Brazil 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Brazil 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 146: Mexico Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Mexico Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Mexico 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Mexico 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 152: Rest of Latin America Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Rest of Latin America Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Rest of Latin America 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Rest of Latin America 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Uterine Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 158: Middle East Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 159: Middle East Historic Review for Uterine Cancer Therapeutics and Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Middle East 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Middle East 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 167: Iran Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Iran Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: Iran 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 170: Iran Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: Iran 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 173: Israel Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Israel Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: Israel 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 176: Israel Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: Israel 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 179: Saudi Arabia Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Saudi Arabia Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: Saudi Arabia 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: Saudi Arabia 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 185: UAE Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: UAE Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: UAE 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 188: UAE Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: UAE 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 191: Rest of Middle East Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Rest of Middle East Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: Rest of Middle East 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: Rest of Middle East 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030
  • AFRICA
    • Uterine Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 197: Africa Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Africa Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: Africa 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2014, 2024 & 2030
    • TABLE 200: Africa Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: Africa 16-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2014, 2024 & 2030

IV. COMPETITION